GSK hosted the third annual RespiVerse Meeting on December 13 and 14 in Bangkok, Thailand. The event brought together ...

Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...

UK pharma major GSK has into an agreement with Chongqing Zhifei Biological Products (Zhifei) to revize the terms on which ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Revised deal with Zhifei to manage near-term challenges GSK shares marginally lower Potential RSV collaboration for initial 10-year term Dec 5 (Reuters) - China's Zhifei (300122.SZ), opens new tab ...

(Alliance News) - GSK PLC on Thursday said it has expanded its shingles vaccine collaboration with Chongqing Zhifei Biological Products Ltd in China, including an extended term length.